Company intelligence / Profile preview

SwiftDuct

Sakhnin, Israel

Ownership: Private
Development stage: Other

Overview

SwiftDuct's first-in-human clinical study demonstrated successful real-time differentiation between bile and pancreatic/mixed juices during ERCP, enabling selective and safer biliary cannulation with the SwiftGlide™ system, thus indicating potential to reduce post-ERCP pancreatitis and minimize need for fluoroscopy. Results from a 14-patient trial were presented at ESGE Days 2024, confirming technical feasibility and clinical promise[2][3][4].

Therapeutic areas: Gastroenterology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

MEDX Xelerator

Beyond the preview

Go deeper on SwiftDuct.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SwiftDuct.

Explore the full profile